Top Markets
#1 Cash Cat Cash Cat +12.09%
#2 Siacoin Siacoin +11.51%
#3 0G 0G +9.75%
#4 Seeker Seeker +9.52%
#5 Arbitrum Arbitrum +8.67%
#6 Metis Metis +5.28%
#7 Story Story +3.96%
#8 MarsCoin MarsCoin +3.88%
#9 Cryptopia Cryptopia +3.87%
#10 Metronome Synth ETH Metronome Synth ETH +3.75%
Coin of the day
Cash Cat Cash Cat
設定
言語
日本
通貨
USD
テーマ
Valerio Therapeutics S.A. Valerio Therapeutics S.A.

Valerio Therapeutics S.A.

ALVIO
株式のランク #14050
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A.... Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
株価
$0.88012714
最終同期: 2026-08-31
時価総額
$439.58M
変化（1日）
-4.01%
変化（1年）
1,131.97%
国
FR
取引 Valerio Therapeutics S.A. (ALVIO)

カテゴリー

Healthcare
Valerio Therapeutics S.A.（ALVIO）の収益
Sep 2026 時点の収益 TTM: 0
Valerio Therapeutics S.A. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Valerio Therapeutics S.A. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH